KNSA Insider Trading
Insider Ownership Percentage: 54.57%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $9,380,104.31
Kiniksa Pharmaceuticals Insider Trading History Chart
This chart shows the insider buying and selling history at Kiniksa Pharmaceuticals by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Kiniksa Pharmaceuticals Share Price & Price History
Current Price: $22.61
Price Change: ▲ Price Increase of +0.45 (2.03%)
As of 03/14/2025 05:00 PM ET
Kiniksa Pharmaceuticals Insider Trading History
Kiniksa Pharmaceuticals Institutional Trading History
Data available starting January 2016
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.
Read More on Kiniksa Pharmaceuticals
Today's Range
Now: $22.61
52 Week Range
Now: $22.61
Volume
595,003 shs
Average Volume
407,191 shs
Market Capitalization
$1.64 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.48
Who are the company insiders with the largest holdings of Kiniksa Pharmaceuticals?
Who are the major institutional investors of Kiniksa Pharmaceuticals?
Which major investors are selling Kiniksa Pharmaceuticals stock?
During the last quarter, KNSA stock was sold by these institutional investors:
- Fairmount Funds Management LLC
- ADAR1 Capital Management LLC
- Jane Street Group LLC
- Arrowstreet Capital Limited Partnership
- Ameriprise Financial Inc.
- Driehaus Capital Management LLC
- Vanguard Group Inc.
- Trexquant Investment LP
During the previous year, company insiders that have sold Kiniksa Pharmaceuticals company stock include:
- Eben Tessari (COO)
- Sanj K Patel (CEO)
- John F Paolini (Insider)
- Michael R Megna (CAO)
- Mark Ragosa (CFO)
Learn More investors selling Kiniksa Pharmaceuticals stock.
Which major investors are buying Kiniksa Pharmaceuticals stock?
In the previous quarter, KNSA stock was bought by institutional investors including:
- Braidwell LP
- JPMorgan Chase & Co.
- Millennium Management LLC
- Raymond James Financial Inc.
- Raymond James Financial Inc.
- Hudson Bay Capital Management LP
- ExodusPoint Capital Management LP
- Deutsche Bank AG